NCT01218633

Dose-response Study of Exendin-9,39 on Glucose Metabolism

A Dose-response Study of the Effects of Exendin-9,39 on Glucose Metabolism, Glucagon and Insulin Secretion and on Insulin Action.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 11 (actual)
• Sponsor: Adrian Vella · Academic / Other
• Sex: All
• Age: 20 Years – 45 Years
• Healthy volunteers: Accepted

Summary

Multiple studies have examined the effect of endogenous GLP-1 secretions by using a competitive antagonist of GLP-1 - Exendin-9,39 - infused at rates of 300pmol/kg/min. However, the presence of an effect does not necessarily imply that this effect is due to the blockade of the endogenous GLP-1 actions at the receptor. It is possible that the supraphysiologic concentrations of Exendin may have effects of its own. To examine the effect of Exendin on glucose metabolism the investigators propose a dose-response study to determine whether the compound has effects in a dose-dependent fashion.

Conditions

• Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1

Interventions

Type	Name	Description
DRUG	saline infusion	saline infused at 30ml/hour
DRUG	GLP-1-9,36 infusion	infused @ 1.2pmol/kg/min
DRUG	Exendin-9,39 at low dose	infused at 30pmol/kg/min
DRUG	Exendin-9,39 at high dose	infused @ 300pmol/kg/min

Timeline

• Start date: 2011-05-01
• Primary completion: 2012-07-01
• Completion: 2012-12-01
• First posted: 2010-10-11
• Last updated: 2013-01-23

Locations

1 site across 1 country: United States